Sellas Life Sciences: REGAL Study Results Due Any Day Are A Major Potential Upside Catalyst [Seeking Alpha]
SELLAS Life Sciences Group, Inc. (SLS)
Last sellas life sciences group, inc. earnings: 11/14 04:41 pm
Check Earnings Report
US:NYSE Investor Relations:
sellaslifesciences.com/investors/overview/default.aspx
Company Research
Source: Seeking Alpha
Extended overall survival in the REGAL trial is interpreted as a strong signal of GPS efficacy, positioning SLS for potential FDA priority review and blockbuster status. SLS009, the company's CDK9 inhibitor, has shown impressive mid-stage results in r/r AML and DLBCL, further de-risking the investment case. I see a 50–100% upside on a positive REGAL catalyst, but acknowledge substantial binary risk and likely capital raise post-readout. Haggerston BioHealth members get exclusive access to our real-world portfolio. See all our investments here » narvo vexar/iStock via Getty Images Investment Overview New York headquartered Sellas Life Sciences ( SLS ) listed on the Nasdaq in August 2017 via a merger with struggling biotech Galena Biopharma - a press release at the time stated: SELLAS' lead asset, galinpepimut-S (GPS), is More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and
Show less
Read more
Impact Snapshot
Event Time:
SLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLS alerts
High impacting SELLAS Life Sciences Group, Inc. news events
Weekly update
A roundup of the hottest topics
SLS
News
- Why I'm Selling Sellas Life Sciences Ahead Of The REGAL Reveal [Seeking Alpha]Seeking Alpha
- A Look At SELLAS Life Sciences Group (SLS) Valuation After New IMPACT AML Clinical Study Agreement [Yahoo! Finance]Yahoo! Finance
- SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into EuropeGlobeNewswire
- SELLAS Life Sciences Group (SLS) Is Up 50.8% After REGAL Trial Nears Final OS Trigger - Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
- SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) [Yahoo! Finance]Yahoo! Finance
SLS
Sec Filings
- 2/17/26 - Form SCHEDULE
- 1/30/26 - Form SCHEDULE
- 1/9/26 - Form 4
- SLS's page on the SEC website